Difference between revisions of "Carboplatin (Paraplatin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
m |
||
| Line 62: | Line 62: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 1989-03-03: Initial approval as palliative treatment of patients with [[Ovarian cancer|ovarian carcinoma]] recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. ''(Based on SWOG 8412 and Swenerton et al. 1992)'' | * 1989-03-03: Initial approval as palliative treatment of patients with [[Ovarian cancer|ovarian carcinoma]] recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. ''(Based on SWOG 8412 and Swenerton et al. 1992)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1986-01-23: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2011-11-25: New additional indication and new dosages for the treatment of [[breast cancer]]. | *2011-11-25: New additional indication and new dosages for the treatment of [[breast cancer]]. | ||
| Line 172: | Line 174: | ||
[[Category:FDA approved in 1989]] | [[Category:FDA approved in 1989]] | ||
| + | [[Category:EMA approved in 1986]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 12:04, 13 June 2023
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Dosing information
Calvert formula
- Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed
Diseases for which it is established (work in progress)
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anal cancer
- Anaplastic glioma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gastric cancer
- Glioblastoma
- Head and neck cancer
- Classical Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Medulloblastoma
- Melanoma
- Nasopharyngeal carcinoma
- Neuroblastoma
- Osteosarcoma
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Upper tract urothelial carcinoma
Diseases for which it was used
Patient drug information
- Carboplatin (Paraplatin) package insert
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1989-03-03: Initial approval as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. (Based on SWOG 8412 and Swenerton et al. 1992)
History of changes in EMA indication
- 1986-01-23: EURD
History of changes in PMDA indication
- 2011-11-25: New additional indication and new dosages for the treatment of breast cancer.
Also known as
- Code name: JM8
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Biocarb | Biocarbo | Bioplatinex | Biovinate | Blastocarb | Bonaplatin | Boplatex | Carbo |
| Carbokem | Carbomedac | Carbomerck | Carboplat | Carboplatine | Carboplatino | Carboplatinum | Carbosin |
| Carbotanil | Carbotec | Carbotinol | Careptin | Carplan | Carplanil | Carpsol | Crobextin |
| Cycloplatin | Cycloplatinum | Emorzim | Erbakar | Ercar | Fauldcarbo | Ifacap | Kemocarb |
| Megaplatin | Nealorin | Neocarb | Neocarbo | Oncocarb | Paraplatin | Paraplatine | Pharmaplatin |
| Platamine CS | Platinwas | Ribocarbo | Tecnocarb | Vancel | CBDCA | ||
References
Categories:
- Drugs
- Intravenous medications
- Platinum agents
- Alkylating agents
- Irritant
- Adult T-cell leukemia-lymphoma medications
- Anal cancer medications
- Anaplastic glioma medications
- Bladder cancer medications
- Breast cancer medications
- Carcinoma of unknown primary medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Glioblastoma medications
- Head and neck cancer medications
- Classical Hodgkin lymphoma medications
- Low-grade glioma medications
- Low-grade glioma, pediatric medications
- Mantle cell lymphoma medications
- Medulloblastoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Nasopharyngeal carcinoma medications
- Neuroblastoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Osteosarcoma medications
- Ovarian cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Endometrial cancer medications
- Upper tract urothelial carcinoma medications
- Pancreatic cancer medications (historic)
- FDA approved in 1989
- EMA approved in 1986
- WHO Essential Cancer Medicine